https://www.selleckchem.com/pr....oducts/pf-06424439.h
underestimating baseline functioning also warrant consideration. To investigate safety and efficacy of MMF in patients with severe or MTX-refractory juvenile localized scleroderma. Consecutive juvenile localized scleroderma patients undergoing systemic treatment were included in a retrospective longitudinal study. Patients treated with MMF because they were refractory or intolerant to MTX (MMF-group) were compared with responders to MTX (MTX-group). Disease activity was assessed by Localized Scleroderma Cutaneous Assessment Tool and
Like
Comment
Share
